Corcept Therapeutics Incorporated or Telix Pharmaceuticals Limited: Who Leads in Yearly Revenue?

Biotech Giants: Corcept vs. Telix in Revenue Growth

__timestampCorcept Therapeutics IncorporatedTelix Pharmaceuticals Limited
Wednesday, January 1, 20142655100028336824
Thursday, January 1, 20155028600032319194
Friday, January 1, 20168132100029404631
Sunday, January 1, 201715920100031769230
Monday, January 1, 201825124700020439380
Tuesday, January 1, 201930648600024186536
Wednesday, January 1, 20203538740004680000
Friday, January 1, 20213659780004898000
Saturday, January 1, 2022401858000155984000
Sunday, January 1, 2023482375000496659000
ngram

Corcept vs. Telix: A Revenue Race Over the Years

In the dynamic world of biotechnology, Corcept Therapeutics Incorporated and Telix Pharmaceuticals Limited have been pivotal players. Over the past decade, these companies have shown remarkable growth in their annual revenues. Corcept Therapeutics, known for its innovative treatments, has seen its revenue skyrocket by over 1,700% from 2014 to 2023. In contrast, Telix Pharmaceuticals, a leader in radiopharmaceuticals, experienced a staggering 17,400% increase in the same period, with a significant leap in 2023.

By 2023, Telix Pharmaceuticals slightly edged out Corcept with a revenue of approximately $497 million, compared to Corcept's $482 million. This fierce competition highlights the rapid advancements and market potential in the biotech sector. As these companies continue to innovate, investors and industry watchers eagerly anticipate who will lead the charge in the coming years.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025